These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

521 related items for PubMed ID: 34151531

  • 1. Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7.
    Banerji CRS, Zammit PS.
    EMBO Mol Med; 2021 Aug 09; 13(8):e13695. PubMed ID: 34151531
    [Abstract] [Full Text] [Related]

  • 2. PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level.
    Banerji CRS, Zammit PS.
    Hum Mol Genet; 2019 Jul 01; 28(13):2224-2236. PubMed ID: 31067297
    [Abstract] [Full Text] [Related]

  • 3. PAX7 target genes are globally repressed in facioscapulohumeral muscular dystrophy skeletal muscle.
    Banerji CRS, Panamarova M, Hebaishi H, White RB, Relaix F, Severini S, Zammit PS.
    Nat Commun; 2017 Dec 18; 8(1):2152. PubMed ID: 29255294
    [Abstract] [Full Text] [Related]

  • 4. PAX7 target gene repression associates with FSHD progression and pathology over 1 year.
    Banerji CRS.
    Hum Mol Genet; 2020 Aug 03; 29(13):2124-2133. PubMed ID: 32347924
    [Abstract] [Full Text] [Related]

  • 5. Expression patterns of FSHD-causing DUX4 and myogenic transcription factors PAX3 and PAX7 are spatially distinct in differentiating human stem cell cultures.
    Haynes P, Kernan K, Zhou SL, Miller DG.
    Skelet Muscle; 2017 Jun 21; 7(1):13. PubMed ID: 28637492
    [Abstract] [Full Text] [Related]

  • 6. A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy.
    Gatica LV, Rosa AL.
    Neuromuscul Disord; 2016 Dec 21; 26(12):844-852. PubMed ID: 27816329
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers.
    van den Heuvel A, Lassche S, Mul K, Greco A, San León Granado D, Heerschap A, Küsters B, Tapscott SJ, Voermans NC, van Engelen BGM, van der Maarel SM.
    Sci Rep; 2022 Jan 26; 12(1):1426. PubMed ID: 35082321
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Facioscapulohumeral Muscular Dystrophy.
    DeSimone AM, Pakula A, Lek A, Emerson CP.
    Compr Physiol; 2017 Sep 12; 7(4):1229-1279. PubMed ID: 28915324
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Influence of DUX4 Expression in Facioscapulohumeral Muscular Dystrophy and Possible Treatments.
    Duranti E, Villa C.
    Int J Mol Sci; 2023 May 30; 24(11):. PubMed ID: 37298453
    [Abstract] [Full Text] [Related]

  • 15. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene.
    Snider L, Geng LN, Lemmers RJ, Kyba M, Ware CB, Nelson AM, Tawil R, Filippova GN, van der Maarel SM, Tapscott SJ, Miller DG.
    PLoS Genet; 2010 Oct 28; 6(10):e1001181. PubMed ID: 21060811
    [Abstract] [Full Text] [Related]

  • 16. Exchange of subtelomeric regions between chromosomes 4q and 10q reverts the FSHD genotype and phenotype.
    Ma Y, Schwager Karpukhina A, Dib C, Gautier C, Hermine O, Allemand E, Vassetzky YS.
    Sci Adv; 2024 May 03; 10(18):eadl1922. PubMed ID: 38691604
    [Abstract] [Full Text] [Related]

  • 17. Myogenic enhancers regulate expression of the facioscapulohumeral muscular dystrophy-associated DUX4 gene.
    Himeda CL, Debarnot C, Homma S, Beermann ML, Miller JB, Jones PL, Jones TI.
    Mol Cell Biol; 2014 Jun 03; 34(11):1942-55. PubMed ID: 24636994
    [Abstract] [Full Text] [Related]

  • 18. Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments.
    Hamel J, Tawil R.
    Neurotherapeutics; 2018 Oct 03; 15(4):863-871. PubMed ID: 30361930
    [Abstract] [Full Text] [Related]

  • 19. Expression of DUX4 in zebrafish development recapitulates facioscapulohumeral muscular dystrophy.
    Mitsuhashi H, Mitsuhashi S, Lynn-Jones T, Kawahara G, Kunkel LM.
    Hum Mol Genet; 2013 Feb 01; 22(3):568-77. PubMed ID: 23108159
    [Abstract] [Full Text] [Related]

  • 20. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
    Jones TI, Chew GL, Barraza-Flores P, Schreier S, Ramirez M, Wuebbles RD, Burkin DJ, Bradley RK, Jones PL.
    Skelet Muscle; 2020 Apr 11; 10(1):8. PubMed ID: 32278354
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.